← back to search

Alex Chehrazi‐Raffle

City of Hope · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, and Cancer Genomics and Diagnostics.
h-index
16
citations
2,531
works
192
NIH funding
primary concept
Medicine
email

Recent publications

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
The Lancet 2024cited by 65position: middledoi
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer 2023cited by 24position: middledoi
An Update on the Treatment of Papillary Renal Cell Carcinoma
Cancers 2023cited by 17position: lastdoi
Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Clinical Cancer Research 2023cited by 15position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Sumanta K. Pal · City of Hope3 papers (2023–2023)Nicolas Sayegh · University of Utah2 papers (2023–2023)Neeraj Agarwal · University of Utah2 papers (2023–2023) · 2 papers (2023–2023) · 1 papers (2023–2023)Geoffrey R. Oxnard · Boston Medical Center1 papers (2023–2023) · 1 papers (2023–2023)Toni K. Choueiri · Harvard University1 papers (2024–2024)Pedro C. Barata · Southwestern Medical Center1 papers (2024–2024) · 1 papers (2023–2023) · 1 papers (2024–2024)Rana R. McKay · The Barbara Ann Karmanos Cancer Institute1 papers (2024–2024)Luís Meza · Yale University1 papers (2023–2023)Robert J. Motzer · Texas Oncology1 papers (2024–2024)Erin Bailey · Huntsman Cancer Institute1 papers (2023–2023)Bradley A. McGregor · Harvard University1 papers (2024–2024)Alexa B. Schrock · GlobalFoundries (United States)1 papers (2023–2023) · 1 papers (2023–2023)Roberto Iacovelli · Cancer Research UK1 papers (2024–2024)Neal Shiv Chawla · Pancreatic Cancer Action Network1 papers (2023–2023)